Newsroom

2025

• May 16, 2025
  【Research Report】　Bridge Report　about Solasia 
• May 16, 2025
  【Research report】　Shared research Q1 FY12/25 Flash Update 
• May 14, 2025
  Business Overview of Pipeline Products(First Quarter of the Fiscal Year Ending December 31, 2025) 

  （402KB）
• May 14, 2025
  Consolidated Financial Results for the Three Months Ended March 31, 2025 (Under IFRS) 

  （328KB）
• Mar 24, 2025
  Solasia Announces Finance via Issuance of Warrant 

  （126KB）
• Mar 05, 2025
  Notice of the 17th Annual General Meeting of Shareholders 

  （350KB）
• Feb 20, 2025
  Announcement on Capital Reduction, Surplus Appropriation (Deficit Disposition), and Election of Directors and Auditor 

  （195KB）
• Feb 12, 2025
  Business Overview of Pipeline Products 

  （293KB）
• Feb 12, 2025
  Consolidated Financial Results for the Fiscal Year Ended December 31, 2024 

  （456KB）
• Feb 12, 2025
  Solasia Announces Booking of Impairment Loss and Difference Between Fiscal 2024 Consolidated Earnings Forecast and Actual Results 

  （106KB）
• Jan 06, 2025
  Solasia Announces Change in Sales Partner for episil in China 

  （163KB）
• Jan 06, 2025
  Solasia Provides Notice of Revision to Its Fiscal 2024 Earnings Forecast 

  （144KB）

2024

• Dec 27, 2024
  Solasia Provides Notice of Revision to Full-Year Earnings Forecast and Progress on Out-Licensing DARVIAS in China 

  （155KB）
• Dec 19, 2024
  Research report about Solasia was updated by Shared Research Inc. 
• Nov 13, 2024
  Consolidated Financial Results for the Nine Months of the Fiscal Year Ending December 31, 2024 (under IFRS) 

  （338KB）
• Nov 13, 2024
  Business Overview of Pipeline Products (Third Quarter of the Fiscal Year Ending December 31, 2024) 

  （413KB）
• Oct 25, 2024
  （Delay）Results of important non-clinical studies of SP-05 

  （157KB）
• Sep 27, 2024
  Solasia Announces Notice of Status of Progress in Out-licensing SP-02 (DARVIAS) in China 

  （190KB）
• Sep 26, 2024
  IR Report：(Bridge-Salon)　about Solasia 
• Aug 14, 2024
  Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2024 (under IFRS) 

  （339KB）
• Aug 14, 2024
  Business Overview of Pipeline Products(Second Quarter of the Fiscal Year Ending December 31, 2024) 

  （391KB）
• May 16, 2024
  Research report about Solasia was updated by Shared Research Inc. 
• May 15, 2024
  Business Overview of Pipeline Products (First Quarter of the Fiscal Year Ending December 31, 2024) 

  （345KB）
• May 15, 2024
  Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2024 (under IFRS) 

  （335KB）
• Apr 17, 2024
  IR Report (Bridge Report) about Solasia 
• Mar 01, 2024
  Notice of the 16th Annual General Meeting of Shareholders 

  （340KB）
• Feb 19, 2024
  Announcement Concerning Election of Five Board Directors and Two Audit & Supervisory Board Members 

  （268KB）
• Feb 16, 2024
  [Delayed] Solasia Announces Finance via Issuance of Unsecured Straight Bond and Warrant 

  （135KB）
• Feb 14, 2024
  Business Overview of Pipeline Products (The Fiscal Year Ending December 31, 2023) 

  （343KB）
• Feb 14, 2024
  Consolidated Financial Results for the Fiscal Year Ended December 31, 2023(under IFRS) 

  （468KB）
• Jan 04, 2024
  Research report about Solasia was updated by Shared Research Inc. 

2023

• Dec 28, 2023
  Solasia Announces Notice of Status of Progress in Out-licensing SP-02 (DARVIAS) in China and Revision of Full-year Earnings Forecast 

  （227KB）
• Dec 22, 2023
  Research report about Solasia was updated by Shared Research Inc. 
• Nov 13, 2023
  Consolidated Financial Results for the Nine Months of the Fiscal Year Ending December 31, 2023 (under IFRS) 

  （344KB）
• Nov 13, 2023
  Business Overview of Pipeline Products ( First Nine months of the Fiscal Year Ending December 31, 2023) 

  （308KB）
• Oct 04, 2023
  Solasia was selected as one of the top five biotech companies in Japan (by LIFE SCIENCE REVIEW) with products at the clinical stage and beyond. 

  （1241KB）
• Oct 04, 2023
  IR Report (Bridge Report) about Solasia 
• Sep 06, 2023
  An article introducing Solasia was published in Newsweek International magazine (September 6, 15 issue). 

  （2136KB）
• Aug 18, 2023
  Shanghai New Office Notice 

  （488KB）
• Aug 18, 2023
  Reprint| The awarding ceremony of the first "Oral Mucositis (OM) Whole Process Management Model Ward" in China was successfully held 

  （1499KB）
• Aug 10, 2023
  Business Overview of Pipeline Products ( First six months of the Fiscal Year Ending December 31, 2023) 

  （259KB）
• Aug 10, 2023
  Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2023 (under IFRS) 

  （339KB）
• Jun 26, 2023
  Research report about Solasia was updated by Shared Research Inc. 
• Jun 16, 2023
  Reprint| ASCO express | Bioadhesive barrier-forming oral gel- episil Effectively Ameliorates acute radiation dermatitis in patients with Breast Cancer 

  （475KB）
• May 17, 2023
  IR Report (Bridge Report) about Solasia 
• May 16, 2023
  Research report about Solasia was updated by Shared Research Inc. 
• May 15, 2023
  Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2023 (under IFRS) 

  （336KB）
• May 15, 2023
  Business Overview of Pipeline Products ( First Quarter of the Fiscal Year Ending December 31, 2023) 

  （258KB）
• Apr 07, 2023
  Research report about Solasia was updated by Shared Research Inc. 
• Mar 20, 2023
  SOLASIA HAS PARTNERED WITH WEP CLINICAL TO SUPPLY DARVIAS [DARVIAS Injection 135mg] UNDER A NAMED PATIENT PROGRAM 

  （147KB）
• Mar 02, 2023
  Notice of the 15th Annual General Meeting of Shareholders 

  （560KB）
• Feb 20, 2023
  Announcement Concerning Election of Five Board Directors and One Audit & Supervisory Board Member 

  （83KB）
• Feb 14, 2023
  Notice Regarding Recording of Impairment Loss (consolidated) and Extraordinary Loss (non-consolidated) for the Fiscal Year Ended December 2022 

  （138KB）
• Feb 14, 2023
  Business Overview of Pipeline Products (The Fiscal Year Ending December 31, 2022) 

  （241KB）
• Feb 14, 2023
  Consolidated Financial Results for the Fiscal Year Ended December 31, 2022 (under IFRS) 

  （498KB）

2022

• Dec 28, 2022
  Research report about Solasia was updated by Shared Research Inc. 
• Nov 25, 2022
  The final results of SP-05 arfolitixorin Phase III study 

  （92KB）
• Nov 25, 2022
  Solasia Announces Booking of Impairment Loss and Revision to Full-Year Earnings Forecasts 

  （196KB）
• Nov 22, 2022
  Solasia Announces Change in Largest Shareholder 

  （199KB）
• Nov 14, 2022
  Solasia Announces Revision to Full-Year Earnings Forecast 

  （162KB）
• Nov 14, 2022
  Consolidated Financial Results for the Nine Months of the Fiscal Year Ending December 31, 2022 (under IFRS) 

  （317KB）
• Nov 14, 2022
  Business Overview of Pipeline Products (Third Quarter of the Fiscal Year Ending December 31, 2022) 

  （735KB）
• Sep 05, 2022
  Solasia Announces Summary of SP-04 PledOx Development Status 

  （108KB）
• Aug 22, 2022
  [Delayed] Solasia Announces Launch of Darvias in Japan 

  （203KB）
• Aug 15, 2022
  Business Overview of Pipeline Products (first six months of the Fiscal Year Ending December 31, 2022) 

  （215KB）
• Aug 15, 2022
  Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2022 (under IFRS) 

  （323KB）
• Aug 04, 2022
  Solasia Announces Topline Data from Phase III AGENT Study of SP-05(arfolitixorin) 

  （195KB）
• Jul 08, 2022
  Solasia acquires episil oral liquid business from Camurus 

  （150KB）
• Jun 30, 2022
  License Transfer from Solasia to Lee’s Pharm for the Sales Promotion of Sancuso and episil in three cities in China 

  （135KB）
• Jun 28, 2022
  Solasia Announces Capital and Business Alliance with Nippon Kayaku Co., Ltd. 

  （181KB）
• Jun 20, 2022
  DARVIAS Injection 135mg (generic name: DARINAPARSIN /development code: SP-02) approved in Japan 

  （109KB）
• May 13, 2022
  Business Overview of Pipeline Products (First Quarter of the Fiscal Year Ending December 31, 2022) 

  （592KB）
• May 13, 2022
  Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2022 (under IFRS) 

  （283KB）
• May 12, 2022
  Solasia announces SP-03 episil Business 

  （71KB）
• Apr 25, 2022
  Solasia’s Partner, Isofol announced start of study data analysis of SP-05 (arfolitixorin) phase III AGENT study 

  （90KB）
• Apr 08, 2022
  IR Report (Bridge Report) about Solasia 
• Mar 31, 2022
  Research report about Solasia was updated by Shared Research Inc. 
• Mar 24, 2022
  Notice of the Resolutions Adopted at the 14th Annual General Meeting of Shareholders 

  （109KB）
• Mar 23, 2022
  Solasia Announces Complete Redemption of Unsecured Straight Bond Issued total 500 Million JPY. (English pdf is not available.)
• Mar 09, 2022
  Notice of the 14th Annual General Meeting of Shareholders 

  （536KB）
• Feb 21, 2022
  Announcement of the matters to be resolved at the Ordinary General Meeting of Shareholders (March 24, 2022.) 

  （143KB）
• Feb 14, 2022
  Solasia Announces Finance via Issuance of Unsecured Straight Bond and Warrant 

  （140KB）
• Feb 09, 2022
  Consolidated Financial Results for the Fiscal Year Ended December 31, 2021 (under IFRS) 

  （471KB）
• Feb 09, 2022
  Business Overview of Pipeline Products (Fourth Quarter of the Fiscal Year Ended December 31, 2021) 

  （331KB）

2021

• Dec 28, 2021
  Research report about Solasia was updated by Shared Research Inc. 
• Dec 10, 2021
  [News] The history of research and development of SP-02 darinaparsin was published in the magazine of Texas A&M University 
• Nov 24, 2021
  Solasia's Partner, Isofol Receives FDA Fast Track Designation for arfolitixorin (SP-05) in Advanced Colorectal Cancer 

  （109KB）
• Nov 24, 2021
  Solasia's Partner, Isofol Receives FDA Fast Track Designation for arfolitixorin (SP-05) in Advanced Colorectal Cancer 

  （109KB）
• Nov 10, 2021
  Business Overview of Pipeline Products (Third Quarter of the Fiscal Year Ending December 31, 2021) 

  （323KB）
• Nov 10, 2021
  Solasia Announces Revision to Full-Year Earnings Forecast 

  （180KB）
• Nov 10, 2021
  Consolidated Financial Results for the Nine Months of the Fiscal Year Ending December 31, 2021 (under IFRS) 

  （298KB）
• Oct 26, 2021
  Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02) 

  （180KB）
• Oct 26, 2021
  Solasia Announces Change in Commercial Partner for SP-02 in Japan 

  （135KB）
• Oct 13, 2021
  IR Report (Bridge Report) about Solasia 
• Oct 12, 2021
  Research report about Solasia was updated by Shared Research Inc. 
• Aug 11, 2021
  Business Overview of Pipeline Products (Second Quarter of the Fiscal Year Ending December 31, 2021) 

  （291KB）
• Aug 11, 2021
  Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2021 (under IFRS) 

  （296KB）
• Jul 27, 2021
  Solasia’s website has been renewed
• Jun 30, 2021
  Solasia Announces Submission of New Drug Application for Anti-cancer Drug DARINAPARSIN for Peripheral T-Cell Lymphoma in Japan 

  （206KB）
• Jun 30, 2021
  Solasia Announces Exercise Price Revisions Associated with Series 12 Warrants 

  （138KB）
• Jun 23, 2021
  Research report about Solasia was updated by Shared Research Inc. 
• May 31, 2021
  Solasia Announces episil was Recommended in Guidelines for Oral Mucositis Caused by Anti-tumor Therapy by CSCO 

  （372KB）
• May 14, 2021
  Solasia Announces Completion of Exercise of Series 11 Warrants 

  （132KB）
• May 12, 2021
  Business Overview of Pipeline Products (First Quarter of the Fiscal Year Ending December 31, 2021) 

  （333KB）
• May 12, 2021
  Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2021 (under IFRS) 

  （365KB）
• May 12, 2021
  IR Report (Bridge Report) about Solasia 
• May 06, 2021
  Solasia’s Partner, Isofol Announces Global Phase III AGENT Study for arfolitixorin(SP-05) Completed Recruitment of Japanese Patients 

  （133KB）
• Mar 31, 2021
  Solasia Announces Complete Redemption of Unsecured Straight Bond Issued total 2,500 Million JPY (English pdf is not available.)
• Mar 29, 2021
  Notice of the Resolutions Adopted at the 13th Annual General Meeting of Shareholders 

  （178KB）
• Mar 22, 2021
  Today’s Online Conference held by Isofol - Start at 22:00 JST (14:00 CET) on March 22 
• Mar 22, 2021
  Solasia Announced iDSMB Recommended to Complete Global Phase III AGENT Study for arfolitixorin(SP-05) as Planned with 440 Patients 

  （136KB）
• Mar 12, 2021
  Notice of the 13th Annual General Meeting of Shareholders 

  （766KB）
• Feb 26, 2021
  Announcement Concerning Partial Amendment to the Articles of Incorporation and Election of Five Board Directors 

  （205KB）
• Feb 10, 2021
  Consolidated Financial Results for the Fiscal Year Ended December 31, 2020 (under IFRS) 

  （367KB）
• Feb 10, 2021
  Business Overview of Pipeline Products (Fourth Quarter of the Fiscal Year Ended December 31, 2020) 

  （304KB）
• Jan 26, 2021
  Solasia posted an analyst coverage webpage

2020

• Dec 15, 2020
  Results from the Prematurely Closed PledOx(SP-04) POLAR Program 

  （74KB）
• Dec 15, 2020
  Solasia Announces Revision to Full-Year Earnings Forecast 

  （159KB）
• Dec 10, 2020
  Solasia’s Partner, Isofol Announces Global Phase III AGENT Study Has Recruited 440 Patients 

  （68KB）
• Nov 13, 2020
  Consolidated Financial Results for the Nine Months of the Fiscal Year Ending December 31, 2020 (under IFRS) 

  （255KB）
• Nov 13, 2020
  Business Overview of Pipeline Products (Third Quarter of the Fiscal Year Ending December 31, 2020) 

  （458KB）
• Oct 05, 2020
  Solasia Announces Non-Clinical Research Results for ATL of DARINAPARSIN at Annual Meeting of Japanese Cancer Association 

  （140KB）
• Sep 23, 2020
  Solasia Announces episil oral liquid Launched in South Korea 

  （166KB）
• Sep 04, 2020
  【News】Following the result of SP-02 pivotal study, Dr. Zingaro, a compound inventor, emeritus professor of Texas A&M University and former M. D. Anderson Cancer Center chemist, was broadcast on TV in Texas, USA (Link to KBTX website) 
• Aug 13, 2020
  Supplementary materials for Aug 13, 2020 announcement 

  （832KB）
• Aug 13, 2020
  Isofol and Solasia Enter License Agreement to Develop and Commercialize ARFOLITIXORIN in Japan 

  （175KB）
• Aug 13, 2020
  Solasia Announces Finance via issuance of Unsecured Straight Bond and Warrant 

  （124KB）
• Aug 12, 2020
  Consolidated Financial Results for the Six Months of the Fiscal Year Ending December 31, 2020 (under IFRS) 

  （275KB）
• Aug 12, 2020
  Business Overview of Pipeline Products (Second Quarter of the Fiscal Year Ending December 31, 2020) 

  （327KB）
• Jul 15, 2020
  Solasia Announces Option Agreement for New Drug Candidate with GeneCare Research Institute 

  （217KB）
• Jun 15, 2020
  Solasia Announces Positive Results of DARINAPARSIN in Pivotal Phase 2 Study for Peripheral T-Cell Lymphoma 

  （144KB）
• May 14, 2020
  Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2020 (under IFRS) 

  （281KB）
• May 14, 2020
  Business Overview of Pipeline Products (First Quarter of the Fiscal Year Ending December 31, 2020) 

  （318KB）
• Apr 06, 2020
  Update on SP-04 (PledOx) (3rd Report) 

  （114KB）
• Mar 30, 2020
  Notice of the Resolutions Adopted at the 12th Annual General Meeting of Shareholders 

  （48KB）
• Mar 13, 2020
  Notice of the 12th Annual General Meeting of Shareholders 

  （235KB）
• Mar 02, 2020
  PledPharma Announces Update on SP-04 (PledOx) Clinical Study Information 

  （71KB）
• Feb 27, 2020
  [Delayed] Announcement Regarding Changes to Executive Management and Conclusion of New Business Agreement with Itochu 

  （123KB）
• Feb 13, 2020
  Consolidated Financial Results for the Fiscal Year Ended December 31, 2019 (under IFRS) 

  （421KB）
• Feb 13, 2020
  Business Overview of Pipeline Products (Fiscal Year Ended December 31, 2019) 

  （314KB）
• Jan 30, 2020
  Solasia Announces Exclusive Out-Licensing Agreement for episil oral liquid with Synex in South Korea 

  （167KB）
• Jan 23, 2020
  PledPharma AB Announces Update on SP-04 (PledOx) Clinical Study Information 

  （68KB）
• Jan 06, 2020
  Solasia Selected as a Loan Margin Trading Issue 

  （69KB）

2019

• Dec 26, 2019
  SOLASIA AND EDITFORCE ENTER INTO JOINT R&D AGREEMENT 

  （76KB）
• Dec 16, 2019
  GLOBAL PHASE III STUDY POLAR-A FULLY RECRUITED 

  （90KB）
• Dec 10, 2019
  Solasia Announces License and Capital Alliance for SP-04 (PledOx) with Maruho 

  （121KB）
• Nov 13, 2019
  Consolidated Financial Results for the Nine Months of the Fiscal Year Ending December 31, 2019 (under IFRS) 

  （232KB）
• Nov 13, 2019
  Business Overview of Pipeline Products (Third Quarter of the Fiscal Year Ending December 31, 2019) 

  （306KB）
• Oct 21, 2019
  Solasia Announces Approval of episil oral liquid in South Korea 

  （164KB）
• Oct 09, 2019
  Solasia Announces Development Strategy for Expanded Indication of PledOx and Amendment of License Agreement 

  （196KB）
• Sep 17, 2019
  Solasia Announces Patient Registration Reached Target Number of Cases for Darinaparsin Phase 2 Pivotal Study for T-Cell Lymphoma 

  （106KB）
• Aug 14, 2019
  Consolidated Financial Results for the Six Months of the Fiscal Year Ending December 31, 2019 (under IFRS) 

  （257KB）
• Aug 14, 2019
  Business Overview of Pipeline Products (Second Quarter of the Fiscal Year Ending December 31, 2019) 

  （276KB）
• Jul 22, 2019
  SOLASIA LAUNCHES EPISIL IN CHINA 

  （273KB）
• Jul 01, 2019
  Solasia Makes First Shipment of episil (SP-03) to China 

  （72KB）
• Jun 27, 2019
  Sancuso Newly Recommended in Guideline for Prevention and Treatment of Nausea and Vomiting Caused by Antitumor Therapies 

  （248KB）
• May 15, 2019
  Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2019 (under IFRS) 

  （252KB）
• May 15, 2019
  Business Overview of Pipeline Products(First Quarter of the Fiscal Year Ending December 31, 2019) 

  （229KB）
• Mar 29, 2019
  Notice of the Resolutions Adopted at the 11th Annual General Meeting of Shareholders 

  （48KB）
• Mar 18, 2019
  SOLASIA LAUNCHES SANCUSO IN CHINA 

  （252KB）
• Mar 14, 2019
  Notice of the 11th Annual General Meeting of Shareholders 

  （466KB）
• Mar 14, 2019
  Solasia Files New Medical Device Application For episil in South Korea 

  （134KB）
• Feb 27, 2019
  Announcement Regarding Reduction in Amounts of Capital Stock & Legal Capital Surplus & Appropriation of Surplus & Election of Directors & Auditors 

  （206KB）
• Feb 21, 2019
  Rapid relief of pain in oral mucositis, New episil oral liquid approved in China 

  （196KB）
• Feb 13, 2019
  Consolidated Financial Results for the Fiscal Year Ended December 31, 2018 (under IFRS) 

  （257KB）
• Feb 13, 2019
  Business Overview of Pipeline Products (Consolidated Financial Results for the Fiscal Year Ended December 31, 2018) 

  （359KB）
• Feb 04, 2019
  Notice of Review Progress of episil oral liquid in China 

  （156KB）

2018

• Dec 26, 2018
  Solasia Initiates Phase III program for PledOx in Japan 

  （104KB）
• Dec 03, 2018
  Notice of Guangzhou Office Opening 

  （235KB）
• Nov 15, 2018
  SP-01 Sancuso First Delivery 

  （72KB）
• Nov 14, 2018
  Consolidated Financial Results for the Nine Months of the Fiscal Year Ending December 31, 2018 (under IFRS) 

  （227KB）
• Nov 14, 2018
  Business Overview of Pipeline Products (Third Quarter of the Fiscal Year Ending December 31, 2018) 

  （152KB）
• Sep 05, 2018
  Announcement Regarding the Pricing for the Issuance of New Shares and Secondary Offering of Shares 

  （53KB）
• Aug 28, 2018
  Announcement Regarding Issuance of New Shares and Secondary Offering of Shares 

  （101KB）
• Aug 17, 2018
  Announcement Concerning Signing of License and Distribution Agreement for SP-02 (darinaparsin injection) in Latin America 

  （167KB）
• Aug 17, 2018
  [Delayed]Solasia acquires exclusive license to develop and commercialize episil (oral liquid) in South Korea 

  （166KB）
• Aug 10, 2018
  Consolidated Financial Results for the Six Months of the Fiscal Year Ending December 31, 2018 (under IFRS) 

  （181KB）
• Jul 24, 2018
  Sancuso, the First Transdermal Patch for the Prevention of CINV Approved in China 

  （252KB）
• Jun 29, 2018
  Announcement Concerning Signing of Commitment Line Agreement 

  （203KB）
• Jun 27, 2018
  Notice of Review Progress of Sancuso in China 

  （177KB）
• Jun 13, 2018
  Announcement Concerning the Development Plan of PledOx 

  （87KB）
• Jun 13, 2018
  Announcement Concerning Signing of Commitment Line Agreement 

  （204KB）
• May 16, 2018
  episil (oral liquid) Launched in Japan 

  （185KB）
• May 15, 2018
  Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2018 (under IFRS) 

  （225KB）
• Mar 30, 2018
  Notice of the Resolutions Adopted at the 10th Annual General Meeting of Shareholders 

  （48KB）
• Mar 15, 2018
  Notice of the 10th Annual General Meeting of Shareholders 

  （316KB）
• Mar 01, 2018
  [Delayed] Consolidated Financial Results for the Fiscal Year Ended December 31, 2017 (under IFRS) 

  （203KB）
• Feb 27, 2018
  Announcement Regarding Change of Directors and Auditors 

  （154KB）
• Feb 09, 2018
  Summary of Financial Results 2017 

  （25KB）
• Feb 09, 2018
  Closing of Phase I Clinical Study of SP-04(PledOx) 

  （83KB）
• Jan 24, 2018
  Notice of Head Office Relocation 

  （121KB）

2017

• Dec 22, 2017
  Notice Regarding Status of SP-01 and Revision to Financial Forecasts 

  （143KB）
• Dec 06, 2017
  [Delayed] Consolidated Financial Results for the Nine Months of the Fiscal Year Ending December 31, 2017 (under IFRS) 

  （235KB）
• Nov 20, 2017
  PledPharma and Solasia enter license agreement to develop and commercialize PledOx in Asia 

  （86KB）
• Nov 14, 2017
  Research report about Solasia is issued by Shared Research Inc. 
• Sep 05, 2017
  [Delayed] Consolidated Financial Results for the Six Months of the Fiscal Year Ending December 31, 2017 (under IFRS) 

  （231KB）
• Sep 04, 2017
  IR Report (Bridge Report) about Solasia 

  （1113KB）
• Jul 07, 2017
  Solasia Announces Approval of episil (oral liquid) in Japan 

  （155KB）
• Mar 24, 2017
  Solasia listed it’s shares to Tokyo Exchange Mothers
• Feb 20, 2017
  Approval for Listing of Shares of Solasia on the Tokyo Stock Exchange Mothers 

  （38KB）
• Feb 16, 2017
  Lee’s Pharmaceutical (HK) Limited and Solasia Pharma Announce License, Promotion and Supply Agreement for episil 

  （133KB）

2016

• Dec 05, 2016
  Meiji Seika Pharma and Solasia Pharma Announce License and Collaboration Agreement for episil 

  （169KB）
• Oct 12, 2016
  Solasia files New Medical Device Applications for episil in Japan and China 

  （192KB）
• Mar 28, 2016
  Solasia initiates Phase II Study of Darinaparsin (SP-02L) for T-Cell Lymphoma 

  （61KB）

2015

• Nov 25, 2015
  Lee’s Pharmaceutical (HK) Limited and Solasia Pharma Announce License, Promotional and Supply Agreement for Sancuso 

  （130KB）
• Mar 30, 2015
  Solasia acquires exclusive license and distribution rights from Camurus for episil oral liquid in Japan and China 

  （47KB）
• Jan 19, 2015
  Meiji Seika Pharma and Solasia Pharma Announce License and Collaboration Agreement for Darinaparsin Injection (SP-02) 

  （160KB）

2014

• Jul 31, 2014
  ZIOPHARM and Solasia Pharma Announce Global License and Collaboration Agreement for Darinaparsin 

  （118KB）

2011

• Oct 26, 2011
  Solasia Announces Initiation of Darinaparsin Injection(SP-02) Phase 1 Study 

  （72KB）
• Mar 08, 2011
  ZIOPHARM and Solasia Pharma Announce License and Collaboration Agreement for Darinaparsin in Asia 

  （69KB）

2010

• Mar 03, 2010
  Solasia Pharma and Kyowa Hakko Kirin enter into a License Agreement for SP-01(Sancuso)in Asia 

  （86KB）

2009

• Jun 01, 2009
  Sancuso clinical trial application filed in China 

  （43KB）

2008

• Oct 01, 2008
  JapanBridge changes name to Solasia Pharma K.K. to reflect focus on asian strategy 

  （59KB）
• Mar 23, 2008
  JapanBridge (Current Solasia Pharma K.K.) and prostrakan partner to develop Sancuso in japan, China & parts of south east asia 

  （69KB）